| Name | Title | Contact Details |
|---|---|---|
Lee Guidetti |
Vice President Talent Acquisition | Profile |
Jeff Kasten |
Vice President, Corporate Strategy, New Product Planning, and Portfolio & Product Management | Profile |
William Hayes |
Head of R&D IT and Informatics | Profile |
Abhishek Gupta |
Director, R&D Development digital capabilities | Profile |
Amy Schacterle |
Senior VP R&D Strategy and Business Management | Profile |
ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NDD Medical Technologies is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.